| 臺大學術典藏 |
2020-05-25T06:51:54Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:27Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Yu C.-J.;Shih J.-Y.;Chiun Hsu;Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chiun Hsu; Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:25Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Gow C.-H.; Chiun Hsu; Chang G.-C.; Yang P.-C.; Su W.-P.; Lin C.-P.; Yang T.-Y.; Yu C.-J.; Chen K.-C.; Shih J.-Y.; Yang C.-H.; Yang C.-H.;Shih J.-Y.;Chen K.-C.;Yu C.-J.;Yang T.-Y.;Lin C.-P.;Su W.-P.;Gow C.-H.;Chiun Hsu;Chang G.-C.;Yang P.-C. |
| 臺大學術典藏 |
2020-03-26T06:54:22Z |
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer
|
Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; ANG YUAN; Shiau C.-W.; Yu C.-J.; Chen K.-F. |
| 臺大學術典藏 |
2020-03-07T06:56:54Z |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
|
Shih J.-Y.;Gow C.-H.;Yu C.-J.;Yang C.-H.;Yih-Leong Chang;Tsai M.-F.;Hsu Y.-C.;Chen K.-Y.;Su W.-P.;Yang P.-C.; Shih J.-Y.; Gow C.-H.; Yu C.-J.; Yang C.-H.; YIH-LEONG CHANG; Tsai M.-F.; Hsu Y.-C.; Chen K.-Y.; Su W.-P.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:38Z |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
|
Shih J.-Y.; Gow C.-H.; Yu C.-J.; Yang C.-H.; YIH-LEONG CHANG; Tsai M.-F.; Hsu Y.-C.; Chen K.-Y.; Su W.-P.; Yang P.-C. |
| 臺大學術典藏 |
2020-01-22T07:46:24Z |
Combined interactions of plant homeodomain and chromodomain regulate NuA4 activity at DNA double-strand breaks
|
MAU-SUN CHANG; Liaw H.; Myung K.; Wu W.-S.; Hung P.-C.; Hung J.-J.; Yang W.-B.; Chang M.-S.; Chen Y.-C.; Shih M.-Y.; Lin Y.-J.; Jiang Z.-D.; Chang S.-B.; Lin J.-Y.; Chia L.-C.; Hsu S.-H.; Su W.-P.;Hsu S.-H.;Chia L.-C.;Lin J.-Y.;Chang S.-B.;Jiang Z.-D.;Lin Y.-J.;Shih M.-Y.;Chen Y.-C.;Chang M.-S.;Yang W.-B.;Hung J.-J.;Hung P.-C.;Wu W.-S.;Myung K.;Liaw H.; Su W.-P. |
| 國立成功大學 |
2020 |
The HLTF–PARP1 interaction in the progression and stability of damaged replication forks caused by methyl methanesulfonate
|
Shiu, J.-L.;Wu, C.-K.;Chang, S.-B.;Sun, Y.-J.;Chen, Y.-J.;Lai, C.-C.;Chiu, W.-T.;Chang, W.-T.;Myung, K.;Su, W.-P.;Liaw, H. |
| 國立成功大學 |
2020 |
Rich p-type-doping phenomena in boron-substituted silicene systems: Boron-substituted silicene
|
Pham, H.D.;Su, W.-P.;Nguyen, T.D.H.;Tran, N.T.T.;Lin, M.-F. |
